Phospho-CHK2 (Thr68) Monoclonal Antibody (ebchk2), PE, eBioscience™, Invitrogen™

Description

Description: This ebchk2 monoclonal antibody recognizes human and mouse Checkpoint Kinase 2 (Chk2) when phosphorylated on threonine 68 (T68). Chk2 is a cell cycle checkpoint regulator and tumor suppressor. Along with Chk1, it plays a critical role in the cellular response to DNA damage, and is particularly important during G2/M transition. Chk2 is activated via phosphorylation on T68 by the kinase ATM, which responds primarily to double-stranded DNA breaks. Upon activation, Chk2 functions include inhibition of Cdc25 family phosphatases and activation of p53, both of which prevent progression of the cell cycle. Abnormal regulation of the ATM-Chk2 pathway is often observed in cancer. Applications Reported: This ebchk2 antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This ebchk2 antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.125 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Staining Protocol: All protocols work well for this monoclonal antibody.

CHEK2 (CHK2) is a serine/threonine kinase and a component of the DNA damage checkpoint pathway. A mutation in CHK2 has been linked to cancer. CHK2 is activated by DNA damage and phosphorylates several modulators of cell cycle control including tumor suppressor proteins. In addition, Chk2 can phosphorylate BRCA1, allowing BRCA1 to restore survival after DNA damage. Chk2 is a putative tumor suppressor protein, with mutations in to the Chk2 gene linked to Li-Fraumeni syndrome, a familiar cancer usually associated with inherited mutations in TP53. Also, mutations in CHK2 are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors.